Therapeutic recommendations for early stage Hodgkin lymphomas
نویسندگان
چکیده
منابع مشابه
XVI. Early stage Hodgkin lymphoma.
In the 1960s and 1970s, patients with clinical stage IA or IIA disease HL apparently confined to the thorax, axillae or neck underwent staging laparotomy with lymph node and liver biopsies and a splenectomy; if histological assessment confirmed the absence of disease below the diaphragm, wide field radiotherapy was recommended [1]. This approach led to prolonged disease-free survival in a signi...
متن کاملTreatment of early-stage Hodgkin lymphoma.
Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD fo...
متن کاملXVII. Radiotherapy in early stage Hodgkin lymphoma.
The treatment of patients with Hodgkin lymphoma (HL) is one of the major success stories in oncology and 60–90% of patients are cured of their malignancy depending on clinical stage and risk factors. Radiotherapy was used to cure patients with HL as early as the 1940s, but more widespread successes came in the 1960s for early stage diseases I A and II A with the use of extended field radiothera...
متن کاملTreatment of Early Stage Hodgkin Lymphoma
Hodgkin lymphoma (HL) is an uncommon lymphoid malignancy which accounts for about 0.5% to 1% of all cancers. In 2010, an estimated 8,490 new cases and 1,320 deaths will occur in the United States (Jemal, Siegel, Xu, et al, 2010). HL incidence appears to be stable over the past few decades, in contrast to the incompletely understood continued increase in frequency of non-Hodgkin lymphomas. HL ha...
متن کاملRadioimmunotherapy for B-cell non-hodgkin lymphomas.
BACKGROUND Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan and 131I-tositumomab) are available in the United States. Both target CD20 with similar clinical outcomes but with unique clinical considerations and radiatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 2018
ISSN: 0007-1048
DOI: 10.1111/bjh.15623